ReviewFrontiers in immunology2013
Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships.
Review in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 87 citations in OpenAlex.
- Article
- Optimizing lipopeptide bioactivity: The impact of non-ionic surfactant dressing.Journal of pharmaceutical analysis · 2024Article
- Microbial lipopeptides: their pharmaceutical and biotechnological potential, applications, and way forward.World journal of microbiology & biotechnology · 2024Review
- Design and Characterization of a Multistage Peptide-Based Vaccine Platform to TargetBioconjugate chemistry · 2023Article
- Article
- The paradigm of prophylactic viral outbreaks measures by microbial biosurfactants.Journal of infection and public health · 2023Review
- Mucosal immunization with lipopeptides derived from conserved regions of SARS-CoV-2 antigens induce robust cellular and cross-variant humoral immune responses in mice.Frontiers in immunology · 2023Article
- Article
- Theranostic efficiency of biosurfactants against COVID-19 and similar viruses - A review.Journal of drug delivery science and technology · 2022Review
- Stereoisomeric PamRSC medicinal chemistry · 2022Article
- Selective Capture of Anti-N-glucosylated NTHi Adhesin Peptide Antibodies by a Multivalent Dextran Conjugate.Chembiochem : a European journal of chemical biology · 2022Article
- Current Prospects in Peptide-Based Subunit Nanovaccines.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Synthesis and functional studies of self-adjuvanting multicomponent anti-HER2 cancer vaccines.RSC advances · 2021Article
- Structural basis of the membrane intramolecular transacylase reaction responsible for lyso-form lipoprotein synthesis.Nature communications · 2021Article
- Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice.Biomaterials · 2021Article
- Toll-like receptor 2 activation induces C-C chemokine receptor 2-dependent natural killer cell recruitment to the peritoneum.Immunology and cell biology · 2020Article
- Biosurfactants Induce Antimicrobial Peptide Production through the Activation ofInternational journal of molecular sciences · 2020Article
- Article
- Glycine Lipids of Porphyromonas gingivalis Are Agonists for Toll-Like Receptor 2.Infection and immunity · 2020Article
- Surface Immunogenic Protein ofVaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide-based vaccines offer several advantages over conventional whole organism or protein approaches by offering improved purity and specificity in inducing immune response. However, peptides alone are generally non-immunogenic. Concerns remain about the toxicity of adjuvants which are critical for immunogenicity of synthetic peptides. The use of lipopeptides in peptide vaccines is currently under intensive investigation because potent immune responses can be generated without the use of adjuvant (thus are self-adjuvanting). Several lipopeptides derived from microbial origin, and their synthetic versions or simpler fatty acid moieties impart this self-adjuvanting activity by signaling via Toll-like receptor 2 (TLR2). Engagement of this innate immune receptor on antigen-presenting cell leads to the initiation and development of potent immune responses. Therefore optimization of lipopeptides to enhance TLR2-mediated activation is a promising strategy for vaccine development. Considerable structure-activity relationships that determine TLR2 binding and consequent stimulation of innate immune responses have been investigated for a range of lipopeptides. In this mini review we address the development of lipopeptide vaccines, mechanism of TLR2 recognition, and immune activation. An overview is provided of the best studied lipopeptide vaccine systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.